Insider trade

Officer purchased ~$622 of CVS shares in the open market

Traded Oct 2, 2024 · Filed Oct 14, 2025

~$622
Reported value · 10 sh @ $62.24: 50
Holds after · shares reported: +36.9%
stock since the trade · S&P 500 +34.3%, $62.24 → $85.20 on Oct 1

Why it stands out

CVS Health's and Chief People Officer spent $622 of their very own money to buy CVS Health shares. Their pile of CVS Health shares grew by 25%.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 2, 2024
Reporting period: Not applicable
Filed with the SEC: Oct 14, 2025

OfficerIndirect holding<$25KHoldings +25%

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$622

Shares × reported transaction price

Size band

<$25K

Ownership change

+25.0%

Purchase shares ÷ estimated pre-transaction holdings, from the filing

Rarity

First purchase in 1 month

Confirmed open-market purchases by the same insider in the available history

Largest by this insider

No

Compared with 1 earlier confirmed purchase

Cluster activity

No other insider purchases within 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Size vs officer pay

This purchase equals less than 1% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2023 ($9.28M)

An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-03. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement

Timing vs results

56 days after results of Aug 7, 2024, 16 days before results of Oct 18, 2024

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Sep 6, 2024 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

2 such cases were open. Tatone v. CVS Health Corporation, docket 1:24-cv-06771, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+1.7%	+0.4%	+1.3%
30 days	-3.5%	+1.0%	-4.6%
90 days	+0.0%	+4.3%	-4.3%
180 days	-3.2%	+3.1%	-6.3%

Past results only. Not a forecast.

Source receipt

Record ID: 0000064803-25-000031
Filed / recorded: Oct 14, 2025, 11:08 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: CVS HEALTH Corp
Issuer CIK: 64803
Ticker: CVS
Reporting person: Heidi B Capozzi
Relationship: Officer
Officer title: EVP and Chief People Officer
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Oct 2, 2024
Transaction code: P
Shares / units: 10
Price per share: $62.24
Acquired / disposed: Acquired (A)
Shares owned after: 50
Ownership form: Indirect — By Trust
Amendment: No

Footnotes from the filing

Shares purchased by a broker exercising discretion for a managed account in the name of a trust for the benefit of the Reporting Person's spouse that were not previously reported due to an error on the part of the broker.